Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.53 |
| ▸ | HBB | P68871 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Limantrafin SCHEMBL25340427 | 1.00 | KDM4E (1.00) | KDM4ERAB9APOLBMEN1KMT2A | |
| Limantrafin SCHEMBL30617842 | 0.98 | KDM4E (0.97) | KDM4ERAB9APOLBMEN1KMT2A | |
| Limantrafin SCHEMBL21597014 | 0.98 | KDM4E (0.97) | KDM4ERAB9APOLBMEN1KMT2A | |
| Limantrafin SCHEMBL30865022 | 0.98 | KDM4E (0.97) | KDM4ERAB9APOLBMEN1KMT2A | |
| Limantrafin SCHEMBL29221528 | 0.98 | KDM4E (0.97) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL28055507 | 0.90 | KDM4E (0.82) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL30601045 | 0.90 | KDM4E (0.82) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL28064235 | 0.90 | KDM4E (0.82) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL31225411 | 0.84 | KDM4E (0.73) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL15055437 | 0.84 | KDM4E (0.73) | KDM4ERAB9APOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260043007-A1 | METHOD FOR PRODUCING CARDIAC MUSCLES | KYOTO UNIVERSITY (JP) | 2026-02-12 | — | — | US | claimed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | claimed |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | claimed |
| US-20250213585-A1 | COMPOSITIONS AND METHODS OF A CONCOMITANT THERAPY OF ALTERNATING ELECTRIC FIELDS AND NOTCH-1 INHIBITOR | SHANGHAI INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY (CN) | 2025-07-03 | — | — | US | claimed |
| EP-4577639-A1 | METHODS AND COMPOSITIONS FOR SMALL MOLECULE BASED PANCREATIC BETA CELL INDUCTION | Trailhead Biosystems Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| EP-4565705-A2 | COMPOSITIONS AND METHODS FOR MODIFYING MULLER GLIAL CELLS | The Johns Hopkins University (US) | 2025-06-11 | — | — | EP | claimed |
| EP-4567105-A1 | METHOD FOR PRODUCING CARDIAC MUSCLES | Kyoto University (JP) | 2025-06-11 | — | — | EP | claimed |
| CN-120051562-A | Method for producing cardiac muscle | 国立大学法人京都大学 | 2025-05-27 | — | — | CN | claimed |
| EP-2793884-B1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2017-11-29 | — | — | EP | claimed |
| US-9296682-B2 | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-03-29 | — | — | US | claimed |
| US-20140329867-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2014-11-06 | — | — | US | claimed |
| EP-2793884-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Ecole Polytechnique Federale de Lausanne (EPFL) (CH) | 2014-10-29 | — | — | EP | claimed |
| WO-2013093885-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Ecole polytechnique fédérale de Lausanne (EPFL) (CH) | 2013-06-27 | — | — | WO | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| WO-2004058713-A1 | DIFFERENTIAL TUMOR CYTOTOXOCITY COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-07-15 | — | — | WO | claimed |
| US-20040132786-A1 | Differential tumor cytotoxicity compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2004-07-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132786-A1 | Differential tumor cytotoxicity compounds and compositions | MIF, FOXM1, MYADM | KDM4E 4087/4885RAB9A 4039/4885POLB 2502/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | KDM4E 1487/4885RAB9A 331/4885POLB 1118/4885 |
| US-20260043007-A1 | METHOD FOR PRODUCING CARDIAC MUSCLES | NOTCH1, NOTCH4, NOTCH3 | KDM4E 123/4885RAB9A 2597/4885POLB 4765/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | KDM4E 794/4885RAB9A 2106/4885POLB 2105/4885 |
| US-20140329867-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | NOTCH3, NOTCH1, NOTCH4 | KDM4E 464/4885RAB9A 3103/4885POLB 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.